Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1910 1
1922 1
1924 1
1925 1
1932 1
1934 1
1944 1
1952 1
1954 1
1955 1
1957 1
1958 1
1959 3
1960 1
1961 1
1962 1
1963 2
1964 1
1965 3
1966 3
1967 4
1968 1
1969 1
1970 2
1972 1
1973 1
1974 1
1975 1
1976 2
1977 3
1978 3
1979 4
1980 3
1981 2
1982 4
1983 8
1984 10
1985 10
1986 6
1987 8
1988 18
1989 10
1990 12
1991 25
1992 19
1993 19
1994 15
1995 32
1996 32
1997 17
1998 18
1999 21
2000 21
2001 29
2002 25
2003 37
2004 29
2005 48
2006 67
2007 55
2008 68
2009 67
2010 77
2011 66
2012 84
2013 107
2014 68
2015 84
2016 96
2017 87
2018 105
2019 82
2020 113
2021 115
2022 102
2023 104
2024 91
2025 84

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,008 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Strober B, et al. Among authors: gordon kb. J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14. J Am Acad Dermatol. 2023. PMID: 36115523 Free article. Clinical Trial.
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Menter A, et al. Among authors: gordon kb. J Am Acad Dermatol. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049. Epub 2019 Nov 5. J Am Acad Dermatol. 2020. PMID: 31703821
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Among authors: gordon kb. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
Risankizumab in moderate-to-severe plaque psoriasis.
Serrano L, Maloney V, Gordon KB. Serrano L, et al. Among authors: gordon kb. Immunotherapy. 2019 Nov;11(16):1357-1370. doi: 10.2217/imt-2019-0116. Epub 2019 Oct 3. Immunotherapy. 2019. PMID: 31578912 Review.
Bimekizumab for the treatment of psoriasis.
Thapar M, Patel M, Gordon K. Thapar M, et al. Among authors: gordon k. Immunotherapy. 2024 Apr;16(7):431-446. doi: 10.2217/imt-2023-0240. Epub 2024 Mar 20. Immunotherapy. 2024. PMID: 38506262 Review.
Gonadotropin-releasing hormone: incredible 50 years.
Paulson RJ, Gordon K. Paulson RJ, et al. Among authors: gordon k. F S Rep. 2023 Mar 29;4(2 Suppl):1-2. doi: 10.1016/j.xfre.2023.03.007. eCollection 2023 Jun. F S Rep. 2023. PMID: 37223765 Free PMC article. No abstract available.
IL-23 inhibitors for moderate-to-severe psoriasis.
Ibler E, Gordon KB. Ibler E, et al. Among authors: gordon kb. Semin Cutan Med Surg. 2018 Sep;37(3):158-162. doi: 10.12788/j.sder.2018.047. Semin Cutan Med Surg. 2018. PMID: 30215632 Review.
2,008 results